Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]

  • Awaiting development
  • GID-TA11663
  • Expected publication date: TBC

Suggested remit: To appraise the clinical and cost effectiveness of Astegolimab (RG-6149) within its marketing authorisation for treating chronic obstructive pulmonary disease (COPD)